Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism TLR7 agonists(Toll like receptor 7 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization Apros Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Colorectal Adenocarcinoma | Phase 1 | US | Apros Therapeutics, Inc.Startup | 20 Jan 2021 |
Liver Cancer | Phase 1 | US | Apros Therapeutics, Inc.Startup | 20 Jan 2021 |
Colonic Cancer | Phase 1 | - | - | 27 Nov 2020 |
NCT04645797 (SITC2022) Manual | Phase 1 | 10 | brdstxxhia(alcsvyatbv) = Between the 25 mg (n=6) and 50 mg (n=4) dose cohorts, APR003 plasma levels were low, with no dose-dependent increase in exposure. APR003 induced a transient yet robust cytokine response peaking around 6-8 hours post-dose and declining by 24 hours. After a week of recovery, all cytokines returned to baseline before the subsequent weekly dose. Cytokine induction in plasma also revealed no dose-dependency. The dose cohort combined geometric mean maximum fold induction over pre-dose of IFNa, IP-10, IL-6, and TNFa were 41-, 21-, 5-, and 2-fold on C1D1 and 107-, 28-, 6-, and 3-fold on C1D15, respectively. Comparing the cytokine levels at 6 hours on the plasma sampling days indicated slightly diminished response on C2D1 compared to C1D1; no APR003 plasma exposure accumulation or reduction was observed on C2D1. roqtqatjvl (kcgxcomnrd ) | Positive | 07 Nov 2022 | ||
Phase 1 | 10 | axfralqekm(gpoeyegaxe) = rzkmiohfhx qpgstgvezi (ivbnpizqmq ) | Positive | 07 Nov 2022 | |||
axfralqekm(gpoeyegaxe) = gmawmcsfqr qpgstgvezi (ivbnpizqmq ) |